| ORIGINAL ARTICLE |
|
| Year : 2015 | Volume
: 18
| Issue : 3 | Page : 327-330 |
|
|
Treatment of pediatric chronic inflammatory demyelinating polyneuropathy: Challenges, controversies, and questions
Jay Desai, Leigh Ramos-Platt, Wendy G Mitchell
Division of Neurology, Children's Hospital Los Angeles, Keck School of Medicine of University of Southern California, USA
Correspondence Address:
Jay Desai
4650 Sunset Boulevard 82, Los Angeles, California 90027
USA
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0972-2327.160065
|
|
|
Pediatric chronic inflammatory demyelinating polyneuropathy (CIDP) is an uncommon acquired disorder of unknown cause, presumed to have an immunological basis. We report 20 patients seen at Children's Hospital Los Angeles over a period of 10 years. The outcome of our patients was favorable in a vast majority with good response to various treatments instituted. However, residual neurologic deficit was common. The choice of treatment modality was empirical and selected by the treating neurologist. Intravenous immunoglobulin (IVIG) and corticosteroids were most commonly utilized for treatment. Plasmapheresis, mycophenolate mofetil, rituximab, cyclophosphamide, azathioprine, and abatacept were added if the patients were refractory to IVIG or became corticosteroid dependent. The spectrum of disease severity ranged from a single monophasic episode, to multiphasic with infrequent relapses with good response to IVIG, to progressive disease refractory to multiple therapies. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
